1. Context {#sec110783}
==========

At present, Hepatitis B Virus (HBV) infection is an important public health problem worldwide. Hepatitis B can lead to serious liver diseases, including cirrhosis, liver cancer. In China, approximately 120 million people are infected with the Hepatitis B Virus ([@A29052R1]). Alavian et al. reported that about 1 million people are infected with HBV in Iran, and 15% to 40% of the patients with hepatitis B may develop cirrhosis or liver cancer ([@A29052R2]). Liver fibrosis is a healing response, but the excessive accumulation of extracellular matrix (ECM) components in the liver often leads to severe forms of liver fibrosis, and ultimately cirrhosis with liver dysfunction ([@A29052R3]-[@A29052R5]). Early cirrhosis may be reversible. Therefore, prompt diagnosis and intervention are critical in limiting disease progression ([@A29052R6]). Clinically, the existing hepatoprotective agents include Ursodesoxycholic acid (UDCA), silibinin, and N-acetylcysteine (NAC).

UDCA is a hydrophilic bile acid, which alters the ratio of hydrophilic-to-hydrophobic components in the bile acid pool. It promotes the secretion of endogenous bile acids such as chenodeoxycholic and lithocholic acid, and improves cholestasis. UDCA is mainly used to treat primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic liver disease, the efficacy is certain. Some studies reported that UDCA protects liver cell membrane and enhances immune function. These mechanisms may be related to the ability of ursodeoxycholic acid to regulate cell cycle, apoptosis and protein biosynthesis of liver cells. Alternatively, the increased pool of hydrophilic bile acid and the stability of the cell membrane may play an important protective role ([@A29052R7], [@A29052R8]). UDCA, which causes minimal damage and is non-toxic to liver cells, is an effective hepatoprotective agent and cholagogue ([@A29052R9]). Results of long-term observational studies showed that ursodeoxycholic acid can significantly reduce the development of hepatic fibrosis ([@A29052R8], [@A29052R10], [@A29052R11]).

Silibinin is derived from milk thistle, an important medicinal plant that is roots, leaves and seeds exert a variety of therapeutic effects, including hepatoprotective, antioxidant, and anti-lipogenic properties ([@A29052R12]). In the United States and Europe, about 65% of patients with liver disease use Chinese medical preparations which include milk thistle as their most common ingredient ([@A29052R13]). Silymarin, a mixture of flavonoids and wood ester pigment compounds, is extracted from milk thistle seeds. Silymarin contains silibinin, silychristin, and silymarin Ning with a large amount of silibinin. it is noteworthy that, silibinin is the main active ingredient of silymarin ([@A29052R14]). In recent years, silibinin has been used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic liver disease ([@A29052R15]).

N-acetylcysteine (NAC) is an intracellular glutathione precursor, which can enhance the activity of glutathione transferase and promote the detoxification of free radicals. nitric oxide (NO) and its metabolite can improve microcirculation, increase tissue oxygen, and enhance the repair of damaged tissue ([@A29052R16], [@A29052R17]). In recent years, clinical studies have demonstrated that NAC is not only effective to treat liver failure caused by excessive acetaminophen (paracetamol), but is also useful for liver disease arising from other causes ([@A29052R18]). NAC reduces serum Total Bilirubin (TBil) and aminotransferases, and increases Prothrombin activity (PTA) in patients with severe chronic hepatitis B ([@A29052R19]).

2. Objectives {#sec110784}
=============

The current study aimed to search randomized controlled clinical trials to evaluate the efficacy of antiviral and non-antiviral hepatoprotective agents combinations on the indexes of liver function and liver fibrosis in patients with hepatitis B.

3. Data Sources {#sec110789}
===============

Papers written in either English or Chinese describing the use of hepatoprotective agents to treat hepatitis and liver fibrosis were retrieved. Using "chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)", the study retrieved papers indexed in the China national knowledge internet (CNKI) (2000 - 2012), Pubmed (19832013), Embase (2000 - 2013) and Cochrane databases (1992 - 2012).

4. Study Selection {#sec110792}
==================

4.1. Inclusion and Exclusion Criteria {#sec110787}
-------------------------------------

### 4.1.1. Inclusion Criteria {#sec110785}

Hepatitis B infection or liver fibrosis; chronic hepatitis B was diagnosed if HBV history or HBV markers were persistently positive for more than six months and serum alanine aminotransferase levels exceeded 80 IU/L, and hepatic fibrosis was estimated by indexes containing the following markers: HA, LN, C-IV, PIIIP ([@A29052R13]). Results indicators including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), TBIL, gamma-Glutamyl Transpeptidase (γ-GGT), Alkaline Phosphatase (ALP), Hyaluronic acid (HA), Laminin (LN), Collagen type IV (CIV), and Procollagen III peptide (PIIIP). Trials were limited to those comparing the efficacy of different drugs or placebo.

### 4.1.2. Exclusion Criteria {#sec110786}

Studies in which non-protective liver drugs were used to treat viral hepatitis or liver fibrosis; animal experiments and reviewed papers that did not contain clinical data; pregnant and lactating female patients with liver disease. The therapy course was less than three weeks; liver biochemical markers were normal.

4.2. Outcome Indicators {#sec110788}
-----------------------

Outcomes were reported in terms of efficacy as follows: 1) Markedly effective: patients underwent full recovery or exhibited significant improvements in their clinical symptoms; levels of ALT, AST, GGT, TBIL and other basic indicators of liver function were restored to within the normal range. 2) Effective: moderate improvement of clinical symptoms, signs and liver function. 3) Ineffective: no obvious improvement or exacerbation of symptoms, signs and liver function indexes.

4.3. Statistical Analysis {#sec110791}
-------------------------

RevMan5.2 software was used to analyze the data. For classified data, risk ratio (RR) and 95% confidence interval (95% CI) were used. For continuous data, weighted mean difference (WMD) and 95% CI were used. If I2 \< 50%, the test was considered uniform with no statistically significant heterogeneity, the fixed effects model was used if I2 \> 50%, a random effects model was used. A Funnel plot was used to evaluate possible publication bias.

5. Data Extraction {#sec110772}
==================

Two authors discussed all data sets before extracting them from the published literature. To avoid subjective bias, names of the authors, publications, year, and country were omitted during the data extraction process. Retrieved data included: (1) liver biochemical indicators: ALT (U/L), GGT (U/L), ALP (U/L) and TBIL (U/L); (2) liver fibrosis markers: HA (μg/L), LN (μg/L), IV-C (μg/L) and PIIIP (μg/L). Disagreements were resolved by discussion and consensus.

6. Results {#sec110801}
==========

6.1. Retrieval Results {#sec110793}
----------------------

Initially, 245 papers were retrieved by screening the title, abstract, and inclusion and exclusion criteria. Finally, 22 standard randomized controlled trials were included, with a total of 1,756 subjects, among whom 893 subjects were in the treated group, and 821 subjects were in the control group ([Table 1](#tbl28482){ref-type="table"}).

###### Basic Characteristics of the Included Studies ^[a](#fn27897){ref-type="table-fn"}^

  Included Studies                         Cases   Intervening Measures   Course of Treatment                                                      Efficacy of Indicators                                                                                                                                                                               
  ---------------------------------------- ------- ---------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ----------------------------------------------
  **Xia et al. (**[@A29052R20]**)**        58      57                     NAC (8 g/d) + basic treatment                                            Basic treatment (Potassium magnesium aspartate 2 g/d + promote the liver cell auxin 0.1 g/d + plasma 200 ml qod + other symptomatic and supportive treatments)                                30 d   TBIL
  **Shi et al. (**[@A29052R21]**)**        20      20                     NAC (8 g/d) + basic treatment                                            Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)   45 d   ALT, AST, TBIL
  **Wang et al. (**[@A29052R19]**)**       50      25                     NAC (8 g/d) + GSH (1.2 g/d)                                              GSH (1.2 g/d)                                                                                                                                                                                 28 d   ALT, AST, TBIL
  **Shohrati et al. (**[@A29052R22]**)**   18      20                     NAC (1.2 g/d) + basic treatment                                          Basic treatment (lamivudine + pegylated interferon + adefovir)                                                                                                                                45 d   ALT, AST, ALP, TBIL
  **Wu et al. (**[@A29052R23]**)**         72      72                     NAC(8 g/d) + basic treatment                                             Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)   45 d   ALT, AST, TBIL
  **Wang et al. (**[@A29052R24]**)**       42      42                     UDCA (0.5 g/d) + GSH (1.2 g/d)                                           Yinzhihuang (30 ml/d)                                                                                                                                                                         8 w    ALT, GGT, ALP, TBIL
  **Fabris et al. (**[@A29052R25]**)**     40      39                     UDCA (0.6 g/d) + lactulose (100-200 g/d)                                 Lactulose (100 - 200 g/d)                                                                                                                                                                     3 w    ALT, AST, GGT, ALP, TBIL
  **Angulo et al. (**[@A29052R26]**)**     21      16                     UDCA (13 - 15 mg/kg/d)                                                   D-penicillamine (the dosage was unclear)                                                                                                                                                      24 w   AST, TBIL
  **Cao et al. (**[@A29052R27]**)**        53      47                     UDCA (0.75 g/d) + Ademethionine (1.0 g/d)                                Kuhuang injection (60 ml/d)                                                                                                                                                                   4 w    ALT, GGT, ALP, TBIL
  **Qureshi et al. (**[@A29052R28]**)**    18      12                     UDCA (0.5 g/d)                                                           Placebo (unclear)                                                                                                                                                                             12 w   ALT
  **Ratziu et al. (**[@A29052R29]**)**     62      64                     UDCA (0.5 g/d)                                                           Placebo (unclear)                                                                                                                                                                             48 w   ALT, AST, GGT, TBIL
  **Tkacz et al. (**[@A29052R12]**)**      45      15                     Silibinin (0.42 g/d)                                                     Placebo (unclear)                                                                                                                                                                             45 d   ALT, AST, TBIL
  **Flisiak et al. (**[@A29052R30]**)**    15      16                     Misoprostol (0.8 g/d)                                                    Silibinin (0.21 g/d)                                                                                                                                                                          12 w   ALT, TBIL
  **Flisiak et al. (**[@A29052R31]**)**    25      25                     Silibinin (0.21 g/d) + misoprostol (0.8 g/d)                             Placebo (unclear)                                                                                                                                                                             24 w   ALT, AST, GGT, TBIL
  **Gu et al. (**[@A29052R32]**)**         33      32                     Silibinin (0.6 g/d) + oxymatrine (0.6 g/d)                               Silibinin (0.6 g/d)                                                                                                                                                                           12 w   ALT, TBIL
  **Bao et al. (**[@A29052R33]**)**        42      42                     Silibinin (0.36 g/d) + Interferon α-16 (300 million U, q.o.d.)           Interferon α-16 (300 million U, qod.)                                                                                                                                                         12 w   ALT, AST
  **Bao et al. (**[@A29052R34]**)**        86      86                     Silibinin (0.36 g/d) + Lamivudine (0.1 g/d)                              Lamivudine (0.1 g/d)                                                                                                                                                                          48 w   ALT, AST, ALP, TBIL
  **Kim et al. (**[@A29052R35]**)**        42      43                     UDCA (0.6 g/d) + Candesartan (0.008 g/d)                                 Candesartan (0.008 g/d)                                                                                                                                                                       24 w   ALT, AST, GGT, TBIL
  **Wang et al. (**[@A29052R36]**)**       45      44                     Silibinin (0.315 g/d) + protect liver treatment + Lamivudine (0.1 g/d)   Protect liver treatment (energy mixture, inosine, salvia miltiorrhiza, promoting liver cell growth hormone and vitamin) + Lamivudine (0.1 g/d)                                                NA     HA, PC, CIV, LN
  **Wu et al. (**[@A29052R37]**)**         40      40                     UDCA (13-15 mg/kg/d) + Fuzhenghuayu Capsules (4.5 g/d)                   Fuzhenghuayu Capsules (4.5 g/d)                                                                                                                                                               48 w   ALT, AST, GGT, TBIL, ALP, HA, LN, IVC, PIIIP
  **Mao et al. (**[@A29052R38]**)**        36      34                     Tanshinone (0.06 g/d) + Oxymatrine (0.6 g/d)                             Tanshinone (0.06 g/d)                                                                                                                                                                         4 w    ALT, AST, TBILI, HA, LN, PIIIP, IVC
  **Zhou et al. (**[@A29052R39]**)**       30      30                     Valsartan (0.08 g/d) + Silibinin (0.14 g/d)                              Silibinin (0.14 g/d)                                                                                                                                                                          12 w   HA, LN, IV-C, PIIIP

^a^ Abbreviations: ALT, Alanine aminotransferase Aminotransferase; ALP; alkaline Alkaline phosphatase Phosphatase; AST, aspartate Aspartate aminotransferase Aminotransferase; CIV collagen Collagen type IV; HA, hyaluronic Hyaluronic acid Acid; LN, laminin Laminin; PIIIP, procollagen Procollagen III peptide Peptide; TBIL, total bilirubin; γ-GGT, gamma-glutamyl Glutamyl transpeptidase Transpeptidase

6.2. Treatment Type {#sec110794}
-------------------

The meta-analysis groups were: 1) liver protective drug plus antiviral drug versus antiviral drug alone to assess efficacy of altering ALT, AST, ALP and TBIL levels ([Table 1](#tbl28482){ref-type="table"}; [Figure 1](#fig21153){ref-type="fig"}); 2) liver protective drug (treatment group) versus placebo to assess protective effects in terms of ALT and TBIL ([Table 1](#tbl28482){ref-type="table"}; [figures 3](#fig21157){ref-type="fig"} and [4](#fig21154){ref-type="fig"}); 3) combination of two hepatoprotective agents versus a single agent in terms of ALT, AST, ALP, GGT, TBIL ([Table 1](#tbl28482){ref-type="table"}; [Figure 4](#fig21154){ref-type="fig"}); 4) one protective agent versus another in terms of normalization rates of ALT and TBIL ([Table 1](#tbl28482){ref-type="table"}; [Figure 5](#fig21155){ref-type="fig"}); 5) evaluation of the effects of a combination of two kinds of protective agents versus a single protective agent in terms of HA, LN, IV-C and PIIIP ([Table 1](#tbl28482){ref-type="table"}; [figures 6](#fig21158){ref-type="fig"} and [7](#fig21159){ref-type="fig"}) as hepatic fibrosis markers.

6.3. Hepatoprotective Drug Combined With Antiviral Drug vs. Antiviral Drug Alone {#sec110795}
--------------------------------------------------------------------------------

Six randomized controlled trials reported on the use of a hepatoprotective drug in combination with an antiviral agent treatment of chronic hepatitis B. The test and control groups included 741 and 645 subjects, respectively. There was a statistically significant heterogeneity between the studies (I2 \> 50%), and hence, a random-effects model was used. Meta-analysis showed that using a combination of hepatoprotective and antiviral drugs was more effective than a single antiviral agent to reduce serum levels of ALT, AST, ALP and TBIL. ALT (WMD = -22.98; 95% CI (-34.98, -10.97)), AST (WMD= -26.20; 95% CI \[-44.60, -7.81\]), ALP (WMD = -56.19; 95% CI \[-85.27, -27.11\]) and TBIL (WMD= -5.58; 95% CI \[-9.50, 1.66\]) ([Figure 1](#fig21153){ref-type="fig"}).

![Meta-Analysis Forest Plots for Effects on ALT, AST, ALP and TBIL Levels\
In patients with chronic hepatitis B infection treated with combination hepatoprotective and antiviral drug vs. antiviral drug alone. Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals.](hepatmon-15-07-29052-i001){#fig21153}

6.4. Hepatoprotective Agents vs. Placebo {#sec110796}
----------------------------------------

Five randomized controlled clinical trials reported the effects of three hepatoprotective agents compared with placebo on liver function indexes in patients with chronic hepatitis B, including ALT and TBIL. In these trials, the control and treatment groups included 144 and 140 subjects, respectively; since there was no significant heterogeneity between the studies (I2 \< 50%), a fixed effect model was applied. Meta-analysis showed that all three hepatoprotective agents significantly decreased ALT levels in patients with hepatitis B. NAC was associated with greater efficacy compared to UDCA and silibinin. The impact of UDCA and silibinin on ALT levels in patients with hepatitis B were considerable: NAC (WMD = -25.66; P = 0.0002, 95% CI \[-39.02, -12.31\]), UDCA (WMD = -22.32; P = 0.03, 95% CI \[-42.28, -2.36\]), silibinin (WMD = -22.40; P = 0.11, 95% CI \[-49.52, 4.72\]) ([Figure 2](#fig21156){ref-type="fig"}).

![Meta-Analysis Forest Plots Indicating Reduced Amounts of ALT\
In patients with chronic hepatitis B infection treated with hepatoprotective drugs vs. placebo. Data are presented as pooled mean difference using a random-effect model and 95 % confidence intervals.](hepatmon-15-07-29052-i002){#fig21156}

UDCA was superior over NAC and silibinin to reduce TBIL in patients with hepatitis B. Meta-analysis showed that NAC (WMD = -2.56; P = 95% CI \[-4.95, -0.17\]), UDCA (WMD = -3.48; 95% CI \[-7.37, -0.31\]), silibinin (WMD = -2.09; 95% CI \[-8.70, 4.52\]). However, the differences were not statistically significant (I2 = 0%) using a fixed-effects model ([Figure 3](#fig21157){ref-type="fig"}).

![Meta-Analysis Forest Plots Describing the Effects of Hepatoprotective Agents vs. Placebo on TBIL Levels\
In patients with chronic hepatitis B infection. Data are presented as pooled relative risks using a fixed-effect model and 95 % confidence intervals.](hepatmon-15-07-29052-i003){#fig21157}

6.5. Two Kinds of Hepatoprotective Agents vs. a Single Hepatoprotective Agent {#sec110797}
-----------------------------------------------------------------------------

Five randomized controlled clinical trials were employed to test the efficacy of two hepatoprotective agents compared to only one to treat patients with chronic hepatitis B. There were 618 subjects in the two hepatoprotective agents, and the single hepatoprotective agent groups, respectively. The heterogeneity between the studies was statistically significant (I2 \> 50%). Using a random effects model, meta-analysis showed that the two hepatoprotective agents group was better than the single agent to reduce ALT, AST, GGT, ALP and TBIL levels in patients with hepatitis B. ALT (WMD=-31.44; 95% CI \[-48.57,-14.32\]), AST (WMD = -14.54; 95% CI \[-29.24, 0.16\]), GGT (WMD = -26.98; 95% CI \[-54.66，0.70\]), ALP (WMD = -29.86; 95% CI \[-52.65, -7.07\]), TBIL (WMD = -4.84; 95% CI \[-9.86, 0.18\]) ([Figure 4](#fig21154){ref-type="fig"}).

![Meta-Analysis Forest Plots for Effects\
In patients with chronic hepatitis B infection treated with the combination of two liver protective drugs vs. one liver protective drug. Data are presented as pooled mean difference using a random-effect model, and 95% confidence intervals.](hepatmon-15-07-29052-i004){#fig21154}

6.6. Effects of two Versus one Hepatoprotective Agent on Recovery of Liver Function in Patients With Hepatitis B {#sec110798}
----------------------------------------------------------------------------------------------------------------

Three randomized controlled clinical trials reported the effects of combining two hepatoprotective drugs compared to a single agent on the recovery rate of liver indicators in patients with hepatitis B; 173 subjects who used a combination of two agents were compared to 123 subjects who used only one agent. The heterogeneity between the studies was statistically significant (I2 = 0%, P = 0.98). Therefore, a fixed-effects model was used. Compared with the single agent group, meta-analysis showed that using a combination of two hepatoprotective drugs was more effective than only one in restoring liver indicators to normal levels (two hepatoprotective agents group vs. single hepatoprotective agent group = 75.2% vs. 49.5%). ALT (72.3% vs. 48.7%, RR = 1.44, 95% CI \[1.01, 2.04\]), TBIL (77.8% vs. 50%, RR = 1.53, 95% CI \[1.21, 1.95\]). The recovery rate of the group that used two hepatoprotective agents was 25.7% higher than the one treated by a single agent, (RR = 1.50, P \< 0.0001, 95% CI \[1.23, 1.83\]) ([Figure 5](#fig21155){ref-type="fig"}).

![Meta-Analysis Forest Plots Indicating the Normalization Rates of ALT and TBIL\
In patients with chronic hepatitis B infection treated with two vs. one hepatoprotective agent. Data are presented as pooled relative risks, adopted fixed-effect model and 95 % confidence intervals, by trial.](hepatmon-15-07-29052-i005){#fig21155}

6.7. Effects of Hepatoprotective Agents on Liver Fibrosis Indexes in Patients With Hepatitis B {#sec110799}
----------------------------------------------------------------------------------------------

Three randomized controlled clinical trials reported the effects of hepatoprotective agents on liver fibrosis markers, HA, IV-C and PIIIP. From the three studies, the test and control groups consisted of 121 and 118 subjects, respectively. The heterogeneity between the studies was statistically significant (I2 \> 50%). Thus, a random-effects model was used. The results indicated that hepatoprotective agents were indeed associated with improved indices of hepatic fibrosis compared to placebo: HA (WMD = -55.65, 95% CI \[-75.00, -36.31\]), IV-C (WMD = -29.23, 95% CI \[-41.21, -17.25\]), PIIIP (WMD = -53.79, 95% CI \[-69.03, -38.55\]) ([Figure 6](#fig21158){ref-type="fig"}).

![Meta-Analysis With Forest Plots Effects of two Hepatoprotective Agents vs. a Single Hepatoprotective Agent on Levels of HA, IV-C and PIIIP\
In patients with liver fibrosis. Data are presented as pooled mean difference using a random-effects model and 95 % confidence intervals, by trials.](hepatmon-15-07-29052-i006){#fig21158}

Four randomized controlled clinical trials reported the effects of combined hepatoprotective agents versus a single agent on the liver fibrosis index, LN. The group representing the combined hepatoprotective agents included 151 subjects, whereas the single hepatoprotective agent group had 148 subjects. There was no significant heterogeneity (I2 \< 50%); therefore, a fixed-effects model was used. Meta-analysis showed that the two hepatoprotective agents was superior to the single one in terms of reducing LN levels (WMD = -33.91, 95% CI \[-40.51, -27.31\]) ([Figure 7](#fig21159){ref-type="fig"}).

![Meta-Analysis Forest Plots of LN Levels in Patients With Liver Fibrosis Infection Treated with Two vs. one Hepatoprotective Agents\
Data are presented as pooled mean difference using a random-effects model, and 95% confidence intervals.](hepatmon-15-07-29052-i007){#fig21159}

6.8. Assessment of Publication Bias {#sec110800}
-----------------------------------

A Funnel plot analysis of bias among 12 trials on the effects of hepatoprotective agents on normalization of ALT, AST and TBIL was conducted, in patients with hepatitis B ([Figure 8](#fig21160){ref-type="fig"}). The Funnel plot showed that the distribution of the samples were asymmetrical, suggesting that some of the test methodologies may have been of low quality, and publication bias may have been present.

![A Funnel plot analysis of the effects of hepatoprotective agents on normalization of ALT, AST and TBIL, in patients with hepatitis B](hepatmon-15-07-29052-i008){#fig21160}

7. Discussion {#sec110802}
=============

The current model is expected to maximize long-term treatment of severe liver disease caused by HBV infection to suppress the virus, improve inflammation and necrosis, and deliver adjuvant therapy to manage complications.

The results of the current study showed that after a certain treatment course of a combined hepatoprotective and antiviral drugs, liver function and fibrosis index decreased in most of the subjects. Combination therapy was more effective than a single hepatoprotective agent to reduce liver cell damage, promote the liver cell membrane and promote the recovery of liver function, and it may delay the formation and development of hepatic fibrosis ([@A29052R38]). Some studies showed a synergistic effect between hepatoprotective agents and antiviral drugs. It may be related to the improvement in drug tolerance due to hepatoprotective agents in patients with hepatitis B ([@A29052R34], [@A29052R40]). In 2006, Qureshi et al reported that large doses of ursodeoxycholic acid reduces ALT levels in patients with hepatitis B ([@A29052R28]). The meta-analysis of the current study showed that acetylcysteine, ursodeoxycholic acid and silibinin significantly reduced ALT, and were a liver function marker in patients with hepatitis B. The reduction in ALT levels by acetylcysteine was better than ursodeoxycholic acid and silibinin. This may be related to the ability of acetylcysteine to inhibit the expression of serum II-18, IFN-γ and NO in the patients with hepatitis B. Some studies stated that acetylcysteine should be used, and that it was more beneficial in early stages of liver disease ([@A29052R21]).

The limitations of the study included the retrospective nature, variability of the quantity, quality and sources of the hepatoprotective agents, and the variability, and effectiveness of the antiviral agents. High-quality multi-center, large sample, randomized, double-blind and controlled clinical trials are necessary to confirm the current observations.

In conclusion, hepatoprotective drugs can effectively improve serum liver markers in patients with liver fibrosis when combined with antiviral or other hepatoprotective agents.
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